A prospective, randomised, crossover study to assess the impact of intravenous lysine acetylsalicylate versus oral aspirin on prasugrel inhibited platelets

Trial Profile

A prospective, randomised, crossover study to assess the impact of intravenous lysine acetylsalicylate versus oral aspirin on prasugrel inhibited platelets

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2015

At a glance

  • Drugs Lysine acetylsalicylate (Primary) ; Prasugrel (Primary) ; Aspirin
  • Indications Acute coronary syndromes
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Oct 2015 New trial record
    • 02 Sep 2015 Primary endpoint (inhibition of platelet aggregation after arachidonic acid at 30min) was met.
    • 02 Sep 2015 Results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top